Lysyl oxidase (LOX) and MMP inhibitors were evidenced to regulate the extracellular matrix remodeling, improving the drug delivery efficacy in in vitro and in vivo breast cancer models [112,113]. The gene discussed is LOX; the disease is breast cancer.